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Abstract 
Artherosis of spiral arteries in uteroplacental beds from pre-eclamptic women resemble those of 
atherosclerosis, characterised by increased plasma lipids and lipoproteins. We hypothesised 1) 
lipoproteins receptors/transporter in placenta would be up-regulated in pre-eclampsia, associated with 
increased maternal and fetal lipoprotein concentrations; 2) expression of these would be reduced in pre-
eclamptic placentae from women delivering small-for-gestational-age (SGA) infants. Placental biopsies, 
maternal and umbilical serum samples were taken from 27 normotensive and 24 pre-eclamptic women. 
Maternal/umbilical cord serum LDL; HDL; total cholesterol and triglycerides were measured. Placental 
mRNA expression of lipoprotein receptors/transporters were quantified using qRT-PCR. Protein 
localisation/expression of LRP-1 in the pre-eclamptic with/without SGA was measured by 
immunohistochemistry. Placental mRNA expression of all genes except PON-1, MTTP and PDIA2 were 
observed. No differences for any lipoprotein receptors/transporters were found between groups; 
however, in the pre-eclamptic group placental LRP-1 expression was lower in SGA delivering mothers 
(n = 7; P=0.036). LRP-1 protein was localised around fetal vessels and Hofbauer cells. This is the first 
detailed study of maternal/fetal lipoprotein concentrations and placental lipoprotein receptor mRNA 
expression in normotensive and pre-eclamptic pregnancies. These findings do not support a role of 
altered lipid metabolism in pre-eclampsia, but may be involved in fetal growth.  
Supplementary keywords: Hypertension; lipids; LDL cholesterol; HDL cholesterol; Triglycerides; 
ABCA1; LRP-1; LDL-R; SRB-1;Fetal growth. 
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Introduction: 
Lipids and Pregnancy 
Gestational hyperlipidemia is a common factor in pregnancy in which the maternal circulating lipid 
profile changes from an anabolic to a catabolic state increasing lipids, specially triglycerides (TG) and 
lipoproteins (1). From the 12th week of gestation, phospholipids, total cholesterol (TC), low density 
cholesterol (LDL), high density cholesterol (HDL) and TG increase in response to oestrogen stimulation 
and insulin resistance (2). Thus, during the first two trimesters, it is common to see maternal fat 
accumulation however, in the third trimester there is enhanced lipolytic activity and decreased 
lipoprotein lipase (LPL) activity in the adipose tissue; consequently, fat storage declines or ceases (3). 
Early in gestation, the lipids are required to develop the fetal brain and central nervous system (4), to 
build cell membranes and as a precursor of bile acids and steroid hormones (2). However, a maternal 
source of lipids are still required until term, but in lower amounts, possibly due to some fetal derived 
lipids from the lipogenic activity in the fetal liver, adrenal and testes (2). Conversely, increased TG 
during pregnancy has been shown to have an augmented risk of pre-eclampsia, preterm birth and fetal 
growth restriction (FGR) (2, 5).  The lipid metabolism and plasma levels are also affected by maternal 
factors such as body mass index (BMI), maternal weight gain, maternal nutrition, pre-pregnancy lipid 
levels and various medical complications of pregnancy such as diabetes. (6). 
 
Pre-eclampsia 
Complicating 2–8% of pregnancies, pre-eclampsia, along with the other hypertensive disorders 
of pregnancy, is one of the three leading causes of maternal morbidity and mortality worldwide (7). This 
disorder increases perinatal outcomes, such as prematurity and FGR (8). Pre-eclampsia is generally 
defined as high blood pressure (systolic blood pressure > 140 mm Hg and/or diastolic blood pressure of 
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> 90 mm Hg) and proteinuria (> 300 mg/24 h) at or after 20 weeks’ gestation (9). The cause of pre-
eclampsia remains unknown, but endothelial dysfunction, leading to compromised uteroplacental 
perfusion and reduced maternal-fetal transport of oxygen and nutrients is thought to be involved (10-13). 
Different lines of evidence indicate that abnormal lipid metabolism is involved in the pathogenesis of 
the disease; with acute atherosis seen in pre-eclamptic uteroplacental beds resembling atherosclerotic 
lesions of coronary arteries (14). The presence of lipoproteins receptors in placental syncytiotophoblast, 
specifically Low Density Lipoprotein Receptor (LDL-R), Low density lipoprotein receptor-related 
protein 1 (LRP-1) and Scavenger Receptor class B type 1 (SRB-1) in third trimester placentae have 
previously been shown (15). Placentae expression of some of these receptors from FGR pregnancies 
with (FGR-S) and without (FGR-M) fetal hemodynamic changes, based on the result of Doppler 
velocimetry of umbilical artery and pulsatility index and from non-FGR control pregnancies have been 
reported. LDL-R mRNA levels in FGR-M were similar to controls but lower in FGR-S. In contrast, 
LDL-R protein was higher in both FGR cases than in the control group. LRP-1 mRNA and protein levels 
were not altered in all FGR cases. SRB-I mRNA was unchanged in FGR, but protein levels were lower 
in FGR-S than in the other groups. They concluded that LDL-R and SRB-I levels are altered in FGR 
pregnancies and maternal plasma concentrations of LDL cholesterol are higher in the control group than 
in the FGR-S group (15). However, these have not previously been examined in relation to pre-
eclampsia. 
 Based on the literature relating to placental and liver cholesterol transport pathways, we chose to 
analyse the maternal and fetal lipoprotein concentrations in combination with placenta mRNA 
expression of LRP-1, LDL-R, SRB-1, ATP-binding cassette transporter A1 (ABCA1), Paraoxonase-
1(PON-1), Microsomal triglyceride transfer protein (MTTP) and Protein disulfideisomerase family A, 
member 2 (PDIA2). 
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 We therefore hypothesised that the expression of those lipoprotein receptors involved in the 
cholesterol pathway in the liver, are up-regulated in pre-eclamptic placentae compared to controls as a 
compensatory factor. In addition, the expression of some of these receptors may be reduced in pre-
eclamptic placentae from women delivering small-for-gestational-age (SGA) infants versus appropriate-
for-gestational-age (AGA) infants. 
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Methods 
Subjects and selection criteria 
The study population consisted of two groups of white European women (27 normotensive, 24 
with pre-eclampsia) (Table 1). Detailed demographics and outcome data have previously been published 
(16). The study was approved by the Hospital Ethics Committee of the Nottingham University 
Hospitals; written informed consent was obtained from each participant. Pre-eclampsia was stringently 
defined as stated in the International Society for the Study of Hypertension in Pregnancy guidelines (9). 
Medical and obstetric histories were obtained for each participant. The corrected birthweight percentile 
for each infant was computed, correcting for gestational age, gender, maternal parity and BMI (17). 
SGA was defined as a centile below the 10th, and AGA when the individualised birthweight ratio was 
between the 10th and 90th percentile (18). Table 2 provides demographic, obstetric, and pregnancy 
description data for the pre-eclamptic women delivering SGA and AGA infants. 
 
Sample collection and measurements 
Before delivery, venous blood samples were taken from mothers and immediately after placental 
delivery, where possible, umbilical cord venous blood was collected. Venous samples were allowed to 
clot prior to centrifugation at 1400g for 10 minutes at 4°C. Serum samples were stored at −80°C prior to 
analysis. The number of fetal serum samples missing was 1 in the control (n = 26) and 10 in the pre-
eclamptic (n = 14) group. All women who took part in this study were labouring and either delivered 
vaginally or by emergency Caesarean section.  
 The lipoproteins (LDL, HDL, TC, TG) were measured using MicroSlide technology on the 
Vitros Fusion 5.1 Chemistry System (New York, USA) following the manufacturers’ instructions. 
Briefly, 200 µl of each sample were uniformly distributed over the entire slide area that contained all the 
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reagents for the selected assays to allow larger molecules to be broken up and penetrate into the reagent 
layer. All samples were analysed in triplicate, with the inter-assay variation being less than 5% and the 
intra-assay variation less than 10%. 
 Full depth placental tissue samples were collected within ten minutes of the placental delivery 
from half way between the cord insertion and periphery of the placentae, avoiding infarcts. The samples 
were immediately rinsed in ice-cold phosphate buffered saline, the membranes removed, snap frozen in 
liquid nitrogen for mRNA analysis. A second samples was fixed in formalin for immunohistochemistry 
analysis. All samples were then stored at -80°C until analysis. 
 
RNA extraction and cDNA synthesis 
Total RNA was extracted from a known amount of placental tissue (~ 100 mg) using 
QIAzollysis reagent (Qiagen, Crawley, UK). RNA concentration and quality of each gene were verified 
spectrophotometrically using the Nanodrop ND-1000 (Nanodrop Technologies, Labtech, Ringmer, UK); 
all of the samples had an A260/A280 ratio >1.96 and were stored at -80°C. RNA (1 μg) was then reverse 
transcribed using the QuantiTect Reverse Transcription kit containing a mix of random primers and 
oligodT (Qiagen, Crawley, UK) in a Primus 96 advanced gradient thermocycler (Peqlab Ltd, Fareham, 
UK). 
 
Quantitative real time polymerase chain reaction (RT-PCR) 
Real-time PCR was carried out with the use of SYBR Green chemistry (2x QuantiFast SYBR 
Green, Qiagen, Crawley, UK) on a RotorGene 6000 (Corbett Research, Sydney, Australia) using the 
primers detailed in Table 3, following our previous protocol (19). Briefly, a pre-PCR cycle was run for 5 
minutes at 95°C followed by 45 cycles of 95°C for 10 s, 60°C for 30 s, and 72°C for 20 s. Melt-curve 
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analysis was performed to confirm the presence of 1 single product and non-template controls run to 
assess contamination. Cycle threshold values were used for analysis, and abundance data were obtained 
by the use of quantified cDNA to generate a standard curve. Standards were quantified using 
densitometry and 10-fold serial dilutions (108 to 101 copies) run in parallel with the samples. Abundance 
data for the genes of interest were normalised to GAPDH, a stably expressed housekeeping gene, 
suitable for human placental samples (20). 
 
Immunohistochemical staining of LRP-1 
 LRP-1 protein expression for the 17 AGA and 7 SGA pre-eclamptic placentae from this cohort 
were analysed by immunohistochemistry. Serial sections of placental tissue were cut (5 µm) in the same 
orientation from paraffin-embedded tissue blocks (Sledge Microtome, Anglia Scientific, Norwich, UK) 
and mounted onto Superfrost plus glass microscope slides (Menzel-Glaser, Braunschweig, Germany). 
Before use, sections were dewaxed by immersion in xylene followed by rehydration in descending 
concentrations of alcohol (3 minutes each). 
 Immunohistochemical staining was performed using the Dako Envision staining kits (Dako Ltd 
Germany). LRP-1 rabbit polyclonal antibody (ARP58562_P050; Aviva Systems Biology, USA) was 
used for immunostaining of paraffin-embedded placental sections; the optimal dilution (1 in 500) was 
optimised. Heat-induced epitope retrieval was achieved by heating in a citrate buffer (pH 6.0) using a 
microwave oven for 15 minutes, followed by incubation for 30 minutes in normal rabbit serum (Sigma-
Aldrich, UK) to block nonspecific binding; slides were then incubated with anti-LRP-1 overnight at 
4°C. A negative control was performed for each test section by incubation with rabbit IgG. Sections 
were dehydrated and cleared in ascending concentrations of alcohol and xylene before mounting in DPX 
(BDH, Poole, United Kingdom). 
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 All of the slides were assessed by the same observer, blinded to pregnancy outcome. For analysis 
of placental sections, digital images of 5 randomly selected, high-power (×400 magnification) fields 
were captured on NIS-Elements F2.20 microscope (Nikon United Kingdom Ltd, Surrey, United 
Kingdom). Quantification of LRP-1 was performed as described previously (19, 21) using the Positive 
Pixel Algorithm of Aperio ImageScope software. This software is able to discriminate between positive- 
and negative-stained pixels and combines the number of positive pixels stained with the intensity of 
these same pixels to produce the value “positivity.” A visual check was also performed to ensure 
accurate discrimination of immunolabeled regions. 
 
Statistical analysis 
All tests were performed using SPSS for Windows version 19. Summary data are presented as 
means ± standard deviation (SD) or median and interquartile range as appropriate, the Student’s t test or 
Mann-Whitney U-tests were used depending on the distribution of the data, after testing using the 
Kolmogorov-Smirnov test. Correlations between the parameters were tested with a Spearman’s Rank 
test. The null hypothesis was rejected where P<0.05. 
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Results 
Subjects 
Demographic, obstetric, and pregnancy description data of the 51 participants are shown in Table 
1; clinical descriptions have previously been published (16). All patients carried singleton pregnancies 
and the women with pre-eclampsia all had moderate-to-severe disease, without HELLP syndrome. The 
neonates from both pregnancy groups survived. The number of fetal serum samples that were missing 
was 1 in the control and 10 in the pre-eclamptic groups. Within the pre-eclamptic group, 7 women 
delivered SGA infants and 17 delivered AGA infants (Table 2); only one women in the normotensive 
control group delivered an SGA infant thus was excluded in this analysis. 
 
Biochemical measurements 
For all maternal and umbilical serum lipoproteins, there were no significant differences (P>0.05) 
between normotensive and pre-eclamptic samples. However, umbilical venous samples had significantly 
lower lipids and lipoproteins concentrations compared to maternal concentrations in both groups, TG 
(normal & pre-eclampsia: P<0.0001); TC (normal & pre-eclampsia: P<0.001); LDL (normal: P=0.003; 
pre-eclampsia: P=0.01) and HDL (normal & pre-eclampsia: P=0.001) (Figure 1). 
 
Placental lipoprotein receptors, transporter and enzyme expression 
The mRNA expression of LDL-R, LRP-1, SRB-1, ABCA1, PON-1, MTTP and PDIA2 in placental 
tissue from normotensive control and women with pre-eclampsia are shown in Table 3. LDL-R, LRP-1, 
SRB-1 and ABCA1 were all found to be expressed in placenta tissue, but there was no expression of 
PON-1, MTTP and PDIA2. The placental mRNA expression of the receptors did not significantly differ 
between groups (P>0.05 for all). 
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Although the numbers were small, we additionally analysed the 10 late-onset pre-eclampsia 
women (>34 weeks’ gestation) separately against the control group to test for any gestational specific 
differences. The same non-significant results were seen for all the maternal and fetal lipoprotein 
concentrations and for the placental expression of the receptors, transporters and enzymes (P > 0.1 for 
all). 
 
Placental lipoprotein receptors expression and SGA  
In the pre-eclamptic group only, we found that those delivering SGA infants had significantly 
lower LRP-1expression compared to AGA group (SGA: 4.72 [3.6, 8.7]; AGA: 20.2 [13.5, 27.1]; 
P=0.036). All the other genes did not show any differences (P>0.05). 
Protein expression of LRP-1 was localised mainly around fetal vessels and Hofbauer cells 
(Figure 2). Visual inspection suggests lower protein expression in the pre-elcamptic placentae delivering 
SGA infants compared to AGA group, although was not significant when analysed semi-quantitatively, 
possibly due to small sample size (median  [IQR]: 0.91 [0.86, 0.95] vs. 0.87 [0.81, 0.89]; P>0.05; Figure 
2).  
 
Maternal, umbilical cord serum and placental tissue 
When maternal and umbilical cord serum lipoprotein concentrations were correlated with 
placental mRNA expression of the lipoprotein receptors, no difference between groups was found (P > 
0.05). In addition, no associations between serum lipoproteins or receptors with birth weights or 
gestational age at delivery were seen (P>0.05 for both). 
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Discussion  
In the present study, we have analysed the lipid profile in women with pre-eclampsia and 
normotensive pregnant women. To the best of our knowledge, this is the first study that has concurrently 
investigated the placental, maternal and fetal lipoprotein system comprehensively in normotensive and 
pre-eclamptic pregnancies, and associated these results with SGA infants, in the third trimester of 
pregnancy.  
Previous studies have reported that hyperlipidemia is enhanced in pre-eclampsia (22, 23) and has 
a negative impact on fetal lipid profiles (24, 25). It has been suggested that dyslipidemia may contribute 
to the increased oxidative stress and endothelial dysfunction and possibly insulin resistance, which 
causes a compensatory increase in insulin concentration, decreased LPL activity and increased TG. 
However, factors that influence pre-eclampsia such as chronic hypertension, obesity, and insulin 
resistance share common features with dyslipidemia, related to oxidative stress and altered vascular 
function. Our data showed no significant differences in maternal and fetal lipoprotein concentrations 
between pre-eclampsia and normotensive controls, which is in line with previous data on maternal levels 
(26). In addition, in the current study the mean BMI was 26 kg/m2 in both groups (Table 1), suggesting 
that the abnormal lipid profile could be associated with obesity (27), and not necessarily with pre-
eclampsia. This could also be a reason why some previous studies have reported increased lipoprotein 
concentrations in pre-eclampsia, who may not have controlled for this. Thus, the results from this study 
do not suggest that changes in the lipoprotein concentrations play a direct key role in pre-eclampsia 
pathology. 
All samples were collected at delivery and in the third trimester of pregnancy. Although not 
matched for gestation, lipoprotein concentrations are increased between the first 2 trimesters and last 
trimester, but are then stable (28), therefore these could be compared between groups even if the 
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gestational age was not exactly the same. Furthermore, the same non-significant results were seen when 
only the term pre-eclamptic samples were compared to controls.  
The highest mRNA expression was ABCA1, followed by LRP-1. A previous study also reported 
that ABCA1 is highly expressed in human placenta (29). LRP-1 is the direct lipoprotein receptor of IDL, 
a precursor of LDL (15). However SRB-1 and LDL-R, the main cholesterol transporters (30), had very 
low expression in third trimester placental tissue, which may suggest that the function of LDL-R and 
SRB-1 may not have an important role towards term, which may reflect a down-regulation due to lipids 
derived from the fetus (2). A previous study at term concluded that SRB-1 does not play a critical role in 
controlling plasma cholesterol concentration even in pregnant women with high or low levels of 
cholesterol (30). Our findings are in agreement with others who have reported a marked ABCA1 
expression level in diverse placental cell types (31) and the presence of LDL-R, LRP-1, SRB-1 in 
placenta tissues (15). However, in contrast to the current data, Wadsack et al., showed lower mRNA 
expression of LDL-R in FGR-S and Stepan et al.,(32) reported higher. Different criteria in selecting the 
study population may account for these differences (32); contrasting protein values have also been 
observed in several studies. In our study, we examined LRP-1 protein localisation and expression due to 
the differences seen in the pre-eclamptic plus SGA group. These data suggest lower expression in the 
SGA group, although this didn’t reach significance, possibly due to small numbers. LRP-1 is highly 
expression in macrophages and therefore it is unsurprising that the expression is localised to the 
macrophages of the placentae (Hofbauer cells). 
It must be noted that cholesterol is not only transported by the receptors but also experimental 
evidence suggests that trophoblast cells efflux cholesterol from cells like any other polarized cells (33). 
Three different mechanisms for cholesterol transportation from the circulation and peripheral cells to 
target tissues have been proposed: 1) aqueous diffusion, a protein independent pathway based on 
15 
 
concentration gradients; 2) the SRB-1mediated bidirectional transport between cells and extracellular 
acceptors and 3) ABCA1 mediated unidirectional efflux to lipid-free apolipoproteins (34, 35). The 
physiological consequences of the regulation of receptors for placental function and fetal development 
are unclear. A yet undefined proportion of cholesterol uptake by placenta may be released into the fetal 
circulation. The remaining placental cholesterol, however, is used for sterol synthesis, principally of 
progesterone. 
When we analysed the relationship between placental genes and SGA, we observed that LRP-1 
was significantly lower in placentae from SGA infants in pre-eclamptic group. A possible mechanism 
for this could be through the matrix metalloproteinase (MMP) family. Membrane-type MMPs (MT-
MMP) can degrade LRP-1 into low molecular-mass fragments. Intact soluble LRP-1 alpha chain (sLRP-
1) is shed into human plasma and has been identified at the blood-brain barrier following ischemia. 
Proteins of the MMP family are involved in the breakdown of extracellular matrix in normal 
physiological processes, such as embryonic development, reproduction and tissue remodelling, as well 
as in diseases processes, such as arthritis and metastasis (36). Increased MMP-2 activity (LRP-1 
mediates its internalisation) may contribute to the endothelial dysfunction that is central to the 
pathophysiology of pre-eclampsia, and/or SGA.  
Further analysis is necessary to understand the cholesterol pathway, especially in relation to fetal 
growth, in particular alterations in FGR pregnancies and gestational diabetes mellitus, which can result 
in extremely high birth weight infants (1). It would also be interesting to study the expression of the 
proprotein convertase subtillisin/kexin type 9 (PCSK9) gene, as it regulates cholesterol metabolism via 
degradation of LDL-R (37). 
This is a preliminary study that contributes to the current knowledge with the need for future 
research. It would also be desirable to examine changes at both mRNA and protein levels of all the 
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lipoprotein receptors, transporters and enzymes. Another limitation of the current study is we did not 
have details of exposure to antenatal steroids and other medications, surgery or timing of the last meal, 
which may influence some of these alterations. Much has to be done to elucidate the placental transport 
in pregnancy pathologies, as the transport mechanism for lipids and lipoproteins is far from being 
understood.  
The findings of this study do not support a direct contribution of lipid metabolism in the 
pathogenesis of pre-eclampsia. However, this is the first study that simultaneously analysed seven 
lipoprotein receptors, transporters and enzymes related to the cholesterol pathway, with the lipids and 
lipoprotein levels (LDL, HDL, TC and TG) in maternal and umbilical cord serum, and in relation to fetal 
growth.  
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Figure Legends 
Figure 1. Serum lipoprotein concentrations in maternal and fetal circulation, from normotensive controls 
and pre-eclampsia. The number of fetal serum samples that were missing were 1 in the control (n = 26) 
and 10 in the pre-eclamptic (n = 14). HDL: high density cholesterol; LDL: low density cholesterol; Mat 
NC: Maternal normal control; Fetal NC: Fetal normal control; Mat PE: Maternal pre-eclampsia; Fetal 
PE: Fetal pre-eclampsia. Data presented as median [IQR].*P< 0.05 between maternal and umbilical 
samples for all lipoproteins. 
 
Figure 2. LRP-1 immunostaining in pre-eclamptic placentae from A) AGA (n = 17) and B) SGA (n = 7) 
delivering mothers and C) IgG negative control. In photomicrographs, positive cells appear in brown; 
magnification x400; scale bar = 100 μm. Protein expression was localised to Hofbauer cells (red arrows) 
and fetal vessels blue arrows). In the graph data is represented as median [IQR].  
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Table 1. Clinical and Biochemical data of subject groups 
Parameter NC (27) PE (24) 
Maternal age, y (mean, SD) 30 + 6.9 31 + 6.1 
Booking body mass index, kg/m2 (mean, SD) 26.2 + 5.4 26.6 + 5.0 
Max. systolic blood pressure outside labour, mm 
Hg (mean, SD) 
116 + 4.6 156 + 7.1* 
Max. diastolic blood pressure outside labour, mm 
Hg (mean, SD) 
76.0 + 3.0 98.0 + 4.5* 
Proteinuria, g/L (median [IQR]) - 1.0 [0.3,11.5] 
Gestational age at delivery, wks (mean, SD) 40 + 1.1 36.7 + 3.8* 
Birth weight, kg (median [IQR]) 
3.5 
[3.3,3.7] 
2.9 [2.0,3.4]* 
Birthweight centile (median [IQR]) 45 [23,62] 13 [1,82] 
SGA infants (n (%)) 1 (3.7) 7 (29.2) 
Preterm deliveries (< 37 weeks’ gestation; n (%)) 0 14 (58.3) 
NC: Normotensive controls; PE: pre-eclampsia. *P<0.05 between normotensive controls and women 
with pre-eclampsia. 
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Table 2. Clinical and Biochemical data of the pre-eclamptic women delivery AGA and SGA infants. 
Parameter PE AGA (17) PE SGA (7) 
Maternal age, y (mean, SD) 32 + 7.8 32 + 2.9 
Booking body mass index, kg/m2 (mean, SD) 27.2 + 4.3 27.1 + 6.8 
Gestational age at delivery, wks (mean, SD) 38 + 2.5 35 + 5 
Birth weight, kg (median [IQR]) 3.2 [3, 3.5] 2 [1.6, 2.4]** 
Birthweight centile (median [IQR]) 47.1 [12.6, 69.4] 0.7 [0.3, 1.9]*** 
PE: pre-eclampsia; AGA: appropriate-for-gestational-age; SGA: small-for-gestational-age. **P=0.001 
and ***P<0.0001 between PE AGA and PE AGA groups. 
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Table 3.Details the forward and reverse primers sequences and BLAST sequences  
Gene 
BLAST sequence 
Accession No. 
Primer Length (bp) 
LDL-R NM_000527.3 
5’-aggacggctacagctaccc-3’ 
5’- ctccaggcagatgttcacg-3’ 
73 
LRP-1 NM_002332.2 
5’-ggtgtcacccacctcaacat-3’ 
5’- agtcggtccagtacacgtttc-3’ 
88 
SRBI NM_005505.4 
5’-catcaagcagcaggtcctta-3’ 
5’-cggagagatagaaggggatagg-3’ 
95 
PON-1 NM_000446.5 
5’-actatagtccaagtgaagttcgagtg-3’ 
5’-atgagccagcaactcagctat-3’ 
110 
ABCA1 NM_005502.2 
5’-tgctgcatagtcttgggactc-3’ 
5’-atcacctcctgtcgcatgt-3’ 
76 
MTTP NM_000253.2 
5’-ggctggtcttcacggtagc-3’ 
5’-gttctcctccccctcgtc-3’ 
88 
PDIA2 NM_006849.2 
5’-ctccaagttcctggacaacg-3’ 
5’-tggaccccatagtggagttg-3’ 
104 
LDL-R: Low-Density Lipoprotein Receptor; LRP-1: Low density lipoprotein receptor related protein 1; 
SRB-1: Scavenger Receptor class B type 1; PON-1: Enzyme paraoxonase-1; ABCA1: ATP-binding 
cassette transporter A1; MTTP: Microsomal triglyceride transfer protein; PDIA2: Protein 
disulfideisomerase family A, member 2 
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Table 3. Placental lipoprotein mRNA expression from NC and PE 
Placenta Normalised 
mRNA expression 
(Median [IQR] ) 
NC (n = 27) PE (n = 24) P 
LDL-R 0.05 [0.03, 0.07] 0.06 [0.045, 0.11] 0.107 
LRP-1 7.0 [5.04, 17.33] 12.3 [5.23, 23.89] 0.503 
SRB-1 0.34 [0.21, 0.51] 0.32 [ 0.24, 0.56] 0.605 
ABCA1 31.38 [20.8, 73.55] 28.8 [19.32, 82.81] 0.942 
LDL-R: Low-Density Lipoprotein Receptor; LRP-1: Low density lipoprotein receptor related protein 1; 
SRB-1: Scavenger Receptor class B type 1; ABCA1: ATP-binding cassette transporter A1. 
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